Baker BROS. Advisors LP Has $68.91 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Baker BROS. Advisors LP increased its stake in Immunocore Holdings PLC by 53.3%, purchasing 807,338 shares, bringing its total holdings to 2,322,656 shares.
• Recent analyst reports show a positive outlook for Immunocore with most giving a "buy" rating, and the stock has an average price target of $56.89.
• Immunocore's latest earnings report showed revenue of $130.65 million, outperforming expectations, while still reporting a loss per share of ($0.20).

Baker BROS. Advisors LP raised its position in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 53.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,322,656 shares of the company's stock after buying an additional 807,338 shares during the period. Immunocore makes up about 0.8% of Baker BROS. Advisors LP's holdings, making the stock its 15th biggest holding. Baker BROS. Advisors LP owned approximately 4.64% of Immunocore worth $68,913,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of IMCR. Barclays PLC grew its stake in Immunocore by 2,044.0% during the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock valued at $608,000 after purchasing an additional 19,663 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Immunocore in the 1st quarter worth about $225,000. GAMMA Investing LLC raised its stake in Immunocore by 3,318.1% during the first quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock valued at $5,670,000 after buying an additional 18,548 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its position in shares of Immunocore by 5.2% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company's stock valued at $209,228,000 after acquiring an additional 351,610 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in Immunocore during the fourth quarter worth $11,897,000. Institutional investors and hedge funds own 84.50% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on IMCR. Deutsche Bank Aktiengesellschaft started coverage on shares of Immunocore in a report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target for the company. Jefferies Financial Group initiated coverage on Immunocore in a research report on Monday, August 25th. They set a "buy" rating and a $48.00 price target on the stock. Oppenheimer boosted their price objective on Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research report on Monday, June 2nd. Finally, Wall Street Zen lowered Immunocore from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Seven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $56.89.

Immunocore Stock Performance

NASDAQ:IMCR traded up $1.94 during mid-day trading on Friday, hitting $37.20. 635,305 shares of the company's stock traded hands, compared to its average volume of 336,556. The firm has a 50 day moving average of $33.50 and a two-hundred day moving average of $31.49. The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -93.00 and a beta of 0.77. The company has a current ratio of 5.89, a quick ratio of 5.86 and a debt-to-equity ratio of 1.01. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $39.33.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The firm had revenue of $130.65 million for the quarter, compared to analyst estimates of $122.96 million. During the same period in the previous year, the company posted ($0.23) earnings per share. The company's quarterly revenue was up 30.0% compared to the same quarter last year. On average, equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.